STOCK TITAN

Erasca to Present at the Guggenheim Oncology Conference 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

On February 1, 2023, Erasca, Inc. (Nasdaq: ERAS) announced its participation in the Guggenheim Oncology Conference 2023. The event will feature a fireside chat with CEO Jonathan E. Lim, M.D., and CFO David M. Chacko at 1:00 PM ET on February 8, 2023. They will also engage in one-on-one investor meetings. A live webcast will be available, with an archived replay accessible for 30 days post-event. Erasca focuses on developing therapies for patients with RAS/MAPK pathway-driven cancers, aiming to be a leader in precision oncology.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Oncology Conference 2023. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat beginning at 1:00 pm Eastern Time on Wednesday, February 8, 2023. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


FAQ

What is the date of Erasca's participation in the Guggenheim Oncology Conference 2023?

Erasca will participate in the Guggenheim Oncology Conference 2023 on February 8, 2023.

Who will represent Erasca at the Guggenheim Oncology Conference 2023?

CEO Jonathan E. Lim, M.D., and CFO David M. Chacko will represent Erasca at the conference.

What time is the fireside chat featuring Erasca's leadership?

The fireside chat will begin at 1:00 PM Eastern Time on February 8, 2023.

Where can I watch the webcast of the Erasca fireside chat?

The webcast can be viewed live on Erasca's website, and an archived replay will be available for 30 days after the event.

What is the focus of Erasca's research and development?

Erasca focuses on therapies for patients with RAS/MAPK pathway-driven cancers.

Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Stock Data

795.25M
282.50M
12.4%
77.06%
11.93%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO